Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Pharmaceuticals Corp. (RXPC) Completes Restructuring with Investors

http://www.tech24.org/66721radient-pharmaceuticals-corp-rxpc-completes-restructuring-with-investors.html

I find it appropriate that ProvistaDx is getting ready to finalize their breast Cancer studies and gearing up for their lung cancer test and Radieny's CIT technology..This is apparent by the two new directors added to the PDX lineup... In oprder for PDX to do that, they will need to go public..They have not shown any signs of going public. Why? Because Radient is the company they will take over..PDX gets to go public and have DR-70 and CIT in their pipeline soon...The skeptics keep stating falsely that Radient is in debt with the investors...I guess they either didn't get the memo or their lack of real due diligence is still evident in their false opinions..The skeptics don't realize that Radient is a private company. AMDL is the Corporation that negotiated with Uni-Pharma and not Radient..Norice how the skeptics never mention AMDL Inc. as a corporation in good standing..They need to dig deeper into AMDL and not the obvious about Radient's temporary positioning..The skeptics continue to post false information about Provista's use of DR-70..If they look closer they will see that the agreement between PDX and Radient allowing Provista to use DR-70 in their Breast and lung cancer tests has a five year protection even if the patents elapsed..We know why Radient allowed them to use DR-70. For making their tests more reliable...One more thing..The skeptics keep posting false information stating that Provista never had a lung cancer test..That is obviously a lie you understand..Check out the Garza report they forgot to find while doing their sloppy homework



Provista Diagnostics is the exclusive U.S. provider of several breakthrough tests including a blood test to aid in the early detection of Alzheimer’s disease, the only FDA cleared smell test, an early detection of breast cancer, lung cancer as well as tests for the early detection of women’s reproductive cancers. The well planned and executed acquisition is expected shortly and would bolster Radient’s value in the open market. In fact, it would help Radient capture significantly more revenues and increase financial projections given that under previous agreements with Provista, Radient was only set to capture a small percentage of the profits being generated from sales of RPC Reagent/Antibodies used in Provista’s tests.

CIT is in human phase III trials in India according to Radient filings and past articles.

Detecting the cancer early using their own diagnostics tests and then aiming to treat it with the ground-breaking technologies proposed by the newly formed NuVax Therapeutics subsidiary- which will also carry out human phase II clinical trials is a bullish proposition which may attract speculators looking to invest in first inline therapies for largely unmet medical needs.

http://www.smallcapnetwork.com/Radient-officials-believe-public-spin-offs-will-bring-full-compliance-and-more-value-to-shareholders/s/article/view/p/mid/5/id/156/

***************************************************************

I disageww with you in some parts about the aussies power at this time..The skeptics want to make people believe that the two they claim as criminals, have no say in any matters..It is up to Jim Green the Chairman of the board...I believe the president and secretary are still running the day to day operations. We know from up to date information from Bloomberg about officers and directors is up to date..Mac never resigned as President and Akio never resigned as Secretary..

************************************************************
Newly appointed Directors of Provista

https://en.wikipedia.org/wiki/Joshua_T._Mendell

Joshua T. Mendell, M.D., Ph.D., is an associate professor of pediatrics and molecular biology and genetics at the Johns Hopkins School of Medicine, where he is a faculty member of the McKusick-Nathans Institute of Genetic Medicine.[1] Mendell is a Howard Hughes Medical Institute early career scientist[2] and a preceptor for two Johns Hopkins graduate programs. His molecular biology research examines microRNA (miRNA) regulation and function, with particular emphasis on miRNAs and cancer.[1]
Training and career

Mendell began working in a molecular biology laboratory when he was a teenager and continued to perform laboratory research as an undergraduate at Cornell University.[2] He graduated with a BA in 1996. Mendell pursued a Ph.D. and M.D. at Johns Hopkins University, receiving the degrees in 2001 and 2003 respectively. He remained at Johns Hopkins as a faculty member.[1]
Research

Mendell and members of his research group investigate post-transcriptional gene regulation. As a graduate student with Harry (Hal) Dietz at Johns Hopkins, Mendell researched how cells recognize and degrade messenger RNA molecules with early stop codons, a process known as nonsense mediated decay.[3][4][5][6][7] Mendell's interest in RNA led him into the field of microRNA.[2]

In 2005, Mendell reported in the journal Nature that a gene often mutated in cancer cells, c-Myc, influences the expression of several miRNAs encoded in a cluster on human chromosome 13. These miRNAs in turn affect the expression of a c-Myc-induced transcription factor, E2F1. This research demonstrated a potentially important role for miRNAs in the development of cancer. Mendell has followed up on this work with publications in high-impact journals including Nature Genetics,[8][9] PNAS,[10] Molecular Cell,[11] Nature,[12][13] and Cell,[14] among others.

In 2009, Mendell reported in the journal Cell that treating mice with therapeutic levels of specific miRNAs could suppress development of liver cancer.[15] The publication generated media interest,[16][17][18] including an article in The Times asking, "Is there a secret to eternal youth?"[19]

Mendell has also published numerous review articles on miRNA regulation and function.[20][21][22]
Family

Mendell credits his father, Ohio State University neurologist Jerry Mendell, with influencing his early interest and involvement in molecular biology research,[2] and Mendell's first scientific publication was co-written with his father and other researchers.[23]

Mendell generated data on c-Myc and miRNAs in collaboration with Kathryn O'Donnell. Mendell and O'Donnell are now married and continue to work together on miRNA-related projects.[2]
Awards and honors

Howard Hughes Medical Institute Early Career Scientist Award (2009)
Leukemia and Lymphoma Society Scholar (2008)
Top Young Investigator of 2007 (Genome Technology Magazine, 2007)
Outstanding Young Scientist in the State of Maryland (Allan C. Davis Medal, 2007)
Rita Allen Foundation Scholar (2006)
March of Dimes Basil O'Connor Scholar (2004)[1]


Yoji Nimura

Like I said last month..Yogi Berra said "It ain't over till it's over" you understand...

Here's Yoji and Boo Boo....

http://investing.businessweek.com/research/stocks/private/person.asp?personId=116964322&privcapId=116889226



http://www.nytimes.com/1995/05/07/style/weddings-janice-e-pomerance-yoji-nimura.html

http://images.azcc.gov/scripts/cgi/dwispart2.pl